GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin

Stephania Martins Bezerra, Tamara Lotan, Sheila Friedrich Faraj, Sarah Karram, Rajni Sharma, Mark Schoenberg, Trinity Bivalacqua, George Jabboure Netto

Research output: Contribution to journalArticle

Abstract

GATA3 is a sensitive marker for urothelial carcinoma. We here evaluate, for the first time, GATA3 expression in small cell carcinoma of bladder and prostate and assess its utility in the differential diagnosis with small cell carcinoma of lung primary. Archival tissues from 60 small cell carcinomas (12 bladder, 15 lung, and 33 prostate primary cases) were used to build 2 tissue microarrays. We also assessed whole slide sections from 10 additional primary small cell carcinomas of bladder. GATA3 nuclear expression was evaluated using standard immunohistochemistry. Intensity (weak, moderate, and strong) and extent of expression were assessed in each tissue microarray spot. Extent positivity was categorized as focal (1%-25%), multifocal (>25%), and diffuse (>75%). Nuclear GATA3 expression was encountered in 7 bladder (7/22, 32%) and 2 lung (2/15, 13%) small cell carcinomas. All 33 primary prostate small cell carcinomas were negative. Among bladder tumors, strong and diffuse (>75%) GATA3 labeling was seen in 3 cases (3/22, 14%); focal positivity was observed in the 4 remaining cases (4/22, 18%). Both positive lung cases had only focal positivity. Our study is the first to reveal GATA3 expression in the small subset of lung small cell carcinoma that should be taken into consideration in assigning site of origin in advanced small cell carcinoma cases. Our novel finding of GATA3 positivity in one-third of bladder small cell carcinoma is of potential value in differentiating small cell carcinomas of prostate origin from those of bladder origin.

Original languageEnglish (US)
Pages (from-to)1682-1687
Number of pages6
JournalHuman Pathology
Volume45
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Small Cell Carcinoma
Prostate
Urinary Bladder
Neoplasms
Small Cell Lung Carcinoma
Lung
Urinary Bladder Neoplasms
Differential Diagnosis
Immunohistochemistry
Carcinoma

Keywords

  • Bladder
  • GATA3 immunohistochemistry
  • Lung
  • Prostate
  • Small cell carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin. / Bezerra, Stephania Martins; Lotan, Tamara; Faraj, Sheila Friedrich; Karram, Sarah; Sharma, Rajni; Schoenberg, Mark; Bivalacqua, Trinity; Netto, George Jabboure.

In: Human Pathology, Vol. 45, No. 8, 2014, p. 1682-1687.

Research output: Contribution to journalArticle

Bezerra, Stephania Martins ; Lotan, Tamara ; Faraj, Sheila Friedrich ; Karram, Sarah ; Sharma, Rajni ; Schoenberg, Mark ; Bivalacqua, Trinity ; Netto, George Jabboure. / GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin. In: Human Pathology. 2014 ; Vol. 45, No. 8. pp. 1682-1687.
@article{6442c5de7b294edfbf41d41bc8262533,
title = "GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin",
abstract = "GATA3 is a sensitive marker for urothelial carcinoma. We here evaluate, for the first time, GATA3 expression in small cell carcinoma of bladder and prostate and assess its utility in the differential diagnosis with small cell carcinoma of lung primary. Archival tissues from 60 small cell carcinomas (12 bladder, 15 lung, and 33 prostate primary cases) were used to build 2 tissue microarrays. We also assessed whole slide sections from 10 additional primary small cell carcinomas of bladder. GATA3 nuclear expression was evaluated using standard immunohistochemistry. Intensity (weak, moderate, and strong) and extent of expression were assessed in each tissue microarray spot. Extent positivity was categorized as focal (1{\%}-25{\%}), multifocal (>25{\%}), and diffuse (>75{\%}). Nuclear GATA3 expression was encountered in 7 bladder (7/22, 32{\%}) and 2 lung (2/15, 13{\%}) small cell carcinomas. All 33 primary prostate small cell carcinomas were negative. Among bladder tumors, strong and diffuse (>75{\%}) GATA3 labeling was seen in 3 cases (3/22, 14{\%}); focal positivity was observed in the 4 remaining cases (4/22, 18{\%}). Both positive lung cases had only focal positivity. Our study is the first to reveal GATA3 expression in the small subset of lung small cell carcinoma that should be taken into consideration in assigning site of origin in advanced small cell carcinoma cases. Our novel finding of GATA3 positivity in one-third of bladder small cell carcinoma is of potential value in differentiating small cell carcinomas of prostate origin from those of bladder origin.",
keywords = "Bladder, GATA3 immunohistochemistry, Lung, Prostate, Small cell carcinoma",
author = "Bezerra, {Stephania Martins} and Tamara Lotan and Faraj, {Sheila Friedrich} and Sarah Karram and Rajni Sharma and Mark Schoenberg and Trinity Bivalacqua and Netto, {George Jabboure}",
year = "2014",
doi = "10.1016/j.humpath.2014.04.011",
language = "English (US)",
volume = "45",
pages = "1682--1687",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin

AU - Bezerra, Stephania Martins

AU - Lotan, Tamara

AU - Faraj, Sheila Friedrich

AU - Karram, Sarah

AU - Sharma, Rajni

AU - Schoenberg, Mark

AU - Bivalacqua, Trinity

AU - Netto, George Jabboure

PY - 2014

Y1 - 2014

N2 - GATA3 is a sensitive marker for urothelial carcinoma. We here evaluate, for the first time, GATA3 expression in small cell carcinoma of bladder and prostate and assess its utility in the differential diagnosis with small cell carcinoma of lung primary. Archival tissues from 60 small cell carcinomas (12 bladder, 15 lung, and 33 prostate primary cases) were used to build 2 tissue microarrays. We also assessed whole slide sections from 10 additional primary small cell carcinomas of bladder. GATA3 nuclear expression was evaluated using standard immunohistochemistry. Intensity (weak, moderate, and strong) and extent of expression were assessed in each tissue microarray spot. Extent positivity was categorized as focal (1%-25%), multifocal (>25%), and diffuse (>75%). Nuclear GATA3 expression was encountered in 7 bladder (7/22, 32%) and 2 lung (2/15, 13%) small cell carcinomas. All 33 primary prostate small cell carcinomas were negative. Among bladder tumors, strong and diffuse (>75%) GATA3 labeling was seen in 3 cases (3/22, 14%); focal positivity was observed in the 4 remaining cases (4/22, 18%). Both positive lung cases had only focal positivity. Our study is the first to reveal GATA3 expression in the small subset of lung small cell carcinoma that should be taken into consideration in assigning site of origin in advanced small cell carcinoma cases. Our novel finding of GATA3 positivity in one-third of bladder small cell carcinoma is of potential value in differentiating small cell carcinomas of prostate origin from those of bladder origin.

AB - GATA3 is a sensitive marker for urothelial carcinoma. We here evaluate, for the first time, GATA3 expression in small cell carcinoma of bladder and prostate and assess its utility in the differential diagnosis with small cell carcinoma of lung primary. Archival tissues from 60 small cell carcinomas (12 bladder, 15 lung, and 33 prostate primary cases) were used to build 2 tissue microarrays. We also assessed whole slide sections from 10 additional primary small cell carcinomas of bladder. GATA3 nuclear expression was evaluated using standard immunohistochemistry. Intensity (weak, moderate, and strong) and extent of expression were assessed in each tissue microarray spot. Extent positivity was categorized as focal (1%-25%), multifocal (>25%), and diffuse (>75%). Nuclear GATA3 expression was encountered in 7 bladder (7/22, 32%) and 2 lung (2/15, 13%) small cell carcinomas. All 33 primary prostate small cell carcinomas were negative. Among bladder tumors, strong and diffuse (>75%) GATA3 labeling was seen in 3 cases (3/22, 14%); focal positivity was observed in the 4 remaining cases (4/22, 18%). Both positive lung cases had only focal positivity. Our study is the first to reveal GATA3 expression in the small subset of lung small cell carcinoma that should be taken into consideration in assigning site of origin in advanced small cell carcinoma cases. Our novel finding of GATA3 positivity in one-third of bladder small cell carcinoma is of potential value in differentiating small cell carcinomas of prostate origin from those of bladder origin.

KW - Bladder

KW - GATA3 immunohistochemistry

KW - Lung

KW - Prostate

KW - Small cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84904601707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904601707&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2014.04.011

DO - 10.1016/j.humpath.2014.04.011

M3 - Article

C2 - 24925221

AN - SCOPUS:84904601707

VL - 45

SP - 1682

EP - 1687

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 8

ER -